ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 181 filers reported holding ENANTA PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is 1.74 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2021 | $237,000 | -63.3% | 4,810 | -68.7% | 0.00% | -66.7% |
Q4 2020 | $646,000 | -18.3% | 15,355 | -11.1% | 0.00% | -25.0% |
Q3 2020 | $791,000 | -8.9% | 17,280 | 0.0% | 0.00% | 0.0% |
Q2 2020 | $868,000 | -3.0% | 17,280 | -0.7% | 0.00% | -33.3% |
Q1 2020 | $895,000 | -59.2% | 17,405 | -51.0% | 0.01% | -45.5% |
Q4 2019 | $2,195,000 | -28.0% | 35,530 | -30.0% | 0.01% | -35.3% |
Q3 2019 | $3,049,000 | -47.7% | 50,742 | -26.6% | 0.02% | -45.2% |
Q2 2019 | $5,831,000 | +1038.9% | 69,102 | +1189.2% | 0.03% | +933.3% |
Q1 2019 | $512,000 | +68.4% | 5,360 | +24.9% | 0.00% | +50.0% |
Q4 2018 | $304,000 | -2.3% | 4,290 | +17.9% | 0.00% | 0.0% |
Q3 2018 | $311,000 | – | 3,640 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Krensavage Asset Management, LLC | 564,102 | $42,184,000 | 14.63% |
Fairmount Funds Management LLC | 387,400 | $28,970,000 | 9.55% |
Soleus Capital Management, L.P. | 318,275 | $23,801,000 | 2.38% |
Darwin Global Management, Ltd. | 166,190 | $12,428,000 | 1.90% |
Paradigm Biocapital Advisors LP | 75,507 | $5,646,000 | 1.61% |
ARMISTICE CAPITAL, LLC | 1,056,000 | $78,968,000 | 1.29% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 150,000 | $11,217,000 | 1.29% |
Portland Global Advisors LLC | 75,869 | $5,673,000 | 0.95% |
FARALLON CAPITAL MANAGEMENT LLC | 1,573,829 | $117,691,000 | 0.59% |
Yorktown Management & Research Co Inc | 10,400 | $778,000 | 0.52% |